FirstTake on Pharma - Pharma News and Analysis Podcast

Latest Episodes:

The FirstTake Podcast – Previewing next week’s JP Morgan healthcare conference Jan 06, 2022

Show notes

FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss the biopharma news of their radars this week and look ahead to next week’s JP Morgan Healthcare conference, which due to the pandemic will take place virtually for the second year in a row.

The FirstTake Podcast – Does 2022 promise a bumper year in pharma M&A? Dec 16, 2021

Show notes

FirstWord Pharma PLUS editors Michael Flanagan, Virginia Li and Simon King discuss whether a spate of deals this week is evidence of an eventful year ahead for bio-pharma M&A, take a closer look at Pfizer’s acquisition of Arena Pharmaceuticals and highlight some of the standout moments from the recent ASH conference.

The FirstTake Podcast – Three doses are better than two Dec 09, 2021

Show notes

FirstWord Pharma PLUS editors Michael Flanagan, Virginia Li and Simon King discuss preliminary data for Pfizer and BioNTech’s COVID-19 vaccine versus Omicron, preview the upcoming annual meeting of the American Hematology Society (ASH) and review recent changes to China’s National Drug Reimbursement List (NDRL).

The First Take – Pharma's pandemic takes a new twist Dec 03, 2021

Show notes

FirstWord Pharma PLUS editors Matthew Dennis and Simon King discuss the potential impact of the Omicron variant on the efficacy of COVID-19 vaccines, how GlaxoSmithKline and Sanofi are making moves to keep their vaccines portfolios at the cutting edge of R&D and whether there is a meaningful future for Merck & Co.’s COVID-19 antiviral molnupiravir after this week’s close-run AdCom vote.

The First Take – Pfizer’s antiviral haul, BMS lays out a growth strategy and Biogen’s week to forget Nov 25, 2021

Show notes

FirstWord Pharma PLUS editors Virginia Li, Michael Flanagan and Simon King discuss more developments in the race to bring COVID-19 antivirals to patients, Bristol Myers Squibb’s long term outlook and the pending departure of veteran Al Sandrock as Biogen’s head of R&D.

The First Take – Pfizer makes migraine move Nov 18, 2021

Show notes

FirstWord Pharma PLUS editors Virginia Li, Michael Flanagan and Simon King discuss impressive data for Pfizer’s COVID-19 antiviral drug, its deal this week to partner up with migraine specialist Biohaven Pharmaceuticals, what the future holds for GlaxoSmithKline’s renal anaemia drug daprodustat and Zai Lab’s move into the neuroscience field.

The First Take – Novartis sells Roche stake for big bucks Nov 04, 2021

Show notes

FirstWord Pharma PLUS editors Virginia Li, Michael Flanagan and Simon King discuss Novartis’ $20 billion windfall from the sale of its 33% stake in crosstown rival Roche, Big Pharma’s increasing interest in protein degradation drugs, Pfizer’s eye-watering COVID-19 vaccine sales and survey results outlining a more complex path forward for Aduhelm than perhaps Biogen would like to admit.

The First Take – Q3 earnings season kicks into gear Oct 28, 2021

Show notes

FirstWord Pharma PLUS editors Virginia Li, Michael Flanagan and Simon King discuss notable highlights from Big Pharma’s third quarter earnings season and the formation of a new gene therapy consortium which includes the FDA and NIH among its founders.

The First Take – Biogen banks on Medicare decision to rescue Aduhelm Oct 21, 2021

Show notes

FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss the early commercial performance of Biogen’s Aduhelm, a setback in the field of COVID-19 antivirals and a landmark approval for the US biosimilars market.

The FirstTake - CAR-T, early-stage breast cancer and OX40 Oct 15, 2021

Show notes

In this episode editors Virginia Li, Michael Flanagan and Simon King talk about notable new disclosures in the field of allogeneic CART therapy, look at the approval of Eli Lilly’s Verzenio for early stage breast cancer, gauge whether early data for drugs targeting OX40 could mark a paradigm shift in the treatment of moderate to severe atopic dermatitis and discuss rumours about the next FDA commissioner.

Our TOPPODCAST Picks

Follow Us

Stay Connected

FirstTake on Pharma – Pharma News and Analysis Podcast

Related Podcasts

Links

Stay Connected